Tobacco Endgame: A Critical Frontier for Lung Cancer Prevention and Equity

The phrase “tobacco endgame” might sound like a public-health ideal rather than a realistic strategy for lung cancer specialists. Yet the concept of eliminating the commercial tobacco epidemic rather than merely controlling it is deeply relevant to those who diagnose, treat, and study lung cancer every day.

Globally, smoking remains the single largest preventable cause of lung cancer, responsible for more than 80% of cases. Even as early detection and treatment technologies advance, new generations remain at risk unless we address the upstream cause.

A true tobacco endgame—one that drives smoking prevalence below 5% or preferably to zero—would be the greatest single contribution to reducing global lung cancer mortality.

From Tobacco Control to Tobacco Elimination

Tobacco endgame strategies represent a paradigm shift from incremental demand-reduction toward structural policies designed to permanently dismantle the commercial tobacco epidemic.

Key approaches include nicotine-reduction standards, supply- and retail-reduction policies, generational sales bans, and outright sales prohibitions, increasingly coupled with expanded cessation and early-detection infrastructure.

1. Very Low Nicotine Cigarettes Nicotine Standards

Very low nicotine cigarette (VLNC) standards target the biological basis of dependence by reducing nicotine to non-addictive levels, with robust evidence that such standards increase quit attempts and reduce smoking prevalence when paired with accessible cessation support. These require cigarettes and other combusted products to contain nicotine at minimally addictive or non-addictive levels.

This strategy could reduce dependence, increase quit attempts, and accelerate cessation at the population level. For example, the US FDA has proposed a nicotine product standard of 0.7 mg nicotine per gram of tobacco.

A nationwide product standard strategy targets the “engine” of the epidemic—nicotine dependence, rather than only limiting youth access or marketing. The perception that VLCNs can result in compensatory smoking has been debunked; VLCNs are not safer or less carcinogenic than regular cigarettes.

2. Retail- and Supply-Reduction Policies

Limiting the number of tobacco outlets or gradually phasing out sales. These include the so-called “sinking-lid” mode (a supply-side policy that involves a regular, required reduction in the total amount of tobacco released to the market for sale to reduce community exposure, particularly in high-burden areas), limiting proximity to schools, ending sales in certain store types, requiring strong retailer licensing with appropriate fees and enforceable penalties (with revenues used to expand tobacco treatment) and implementing a planned phase-down of licenses over time.

This is important because retail availability is a driver of uptake and relapse, especially where retail density is concentrated in lower-income and racially minoritized communities. The population implication of this is that the market shrinks by design, year after year, pushing consumption down structurally rather than relying on individual behavior change.

3. Nicotine-Free Generation Policies

Banning sales to anyone born after a given year. For example, the Maldives implemented a generational tobacco ban effective November 1, 2025, applying to people born on or after January 1, 2007.

There is a similar ban in Brookline, Massachusetts, USA. They implemented a “born on or after Jan 1, 2000” policy in 2021, and it has been upheld by the Massachusetts high court. Currently, more than 21 localities in Massachusetts have approved such regulations. The United Kingdom’s (UK) Tobacco and Vapes Bill (2024–25) proposes a generational ban (born on or after January 1, 2009) and is tracked in UK Parliament briefings; health leaders have framed it as a historic opportunity. This strategy represents a symbolic and practical shift toward a tobacco-free future.

4. Ending the Sales of all Commercial Tobacco Products

Early adopters of this strategy include Beverly Hills and Manhattan Beach in California, USA. They ended most tobacco sales on January 1, 2021, to reduce smoking-related health issues.

Specifically, sales of cigarettes, vaping products, or any tobacco products are prohibited in pharmacies, grocery stores, gas stations, and convenience stores. Research has demonstrated the efficacy of this policy and that it did not increase cross-border sales.

5. Banning the Sales of Filtered Tobacco Products

This strategy prohibits the sale of filtered cigarettes and cigars to protect public health and the environment. For example, Santa Cruz County in California adopted an ordinance banning filtered cigarettes/cigars contingent on multiple local jurisdictions adopting similar measures.

The policy is set to take effect January 1, 2027, in Santa Cruz County and the City of Santa Cruz, and July 1, 2027, in Capitola. The rationale is that filters do not make smoking safer, and if filters are banned, the most common cigarette design is disrupted, potentially reducing product appeal while also addressing tobacco product waste (plastic pollution and litter).

6. Integration of Endgame Policies with Cessation and Lung Cancer Screening

Endgame policies are strongest when paired with high-reach cessation treatment, proactive clinical identification (screening for tobacco use), and lung cancer screening for eligible high-risk patients. This approach will strengthen the WHO FCTC Article 14 on cessation and improve lung cancer screening uptake and early detection.

Practical integration includes embedding cessation in every endgame rollout, such as provision of free quitline access, opt-out treatment referrals, NRT starter kits, and expanding services in high-burden areas, e.g., community health centers, safety-net hospitals, perinatal settings, and behavioral health. Endgame policy moments (implementation dates, retailer transitions) can be used to launch cessation campaigns and lung cancer screening outreach.

Equity and Global Relevance

Tobacco endgame policies are not one-size-fits-all. Smoking prevalence and lung cancer burden are highest among those facing poverty, limited healthcare access, and chronic stress. Without intentional design, endgame strategies could inadvertently widen disparities.

For instance, if retail-reduction policies leave only certain communities with remaining outlets or illicit supply. Equity-oriented implementation must therefore accompany any national, regional, state, or local endgame plan.

For the lung cancer community, this means supporting research and interventions that address vulnerable populations such as rural residents, people with mental healthor substance-use disorders, and racial/ethnic minorities disproportionately burdened by tobacco-related disease.

Opportunities for the Thoracic-Oncology Community

• Integrate cessation deeply into lung cancer screening and treatment programs.
• Strengthen data collection through standardized documentation of smoking and nicotine use in clinical trials.
• Advance cross-disciplinary research connecting policy exposure to incidence and outcomes.
• Advocate globally through IASLC networks, supporting low- and middle-income countries.
• Educate the workforce by incorporating endgame principles into training and multidisciplinary care.

Challenges Ahead

Implementation of endgame policies will face predictable resistance. These include pushbacks from the tobacco industry, concerns about enforcement, and debates about personal choice.

The endgame must also anticipate product substitution and illicit trade, ensure robust surveillance, enforcement, and continued access to evidence-based cessation interventions such as medications and counseling. As nicotine alternatives proliferate, careful evaluation of their net impact on lung cancer risk and population health will be essential.

The Endgame is the Beginning of True Prevention

The lung cancer community stands at a pivotal crossroads. Breakthroughs in screening, precision medicine, and immunotherapy have extended lives, but the next great frontier lies in preventing the disease altogether. The tobacco endgame is not a peripheral policy ambition; it is an essential strategy in realizing a world without lung cancer caused by tobacco.

For clinicians, researchers, and advocates within IASLC, embracing the endgame means expanding our scope—from the molecular to the societal, from individual treatment to population transformation. By integrating endgame science, advocacy, and equity into the global lung cancer agenda, we can help ensure that future generations need not face the devastating legacy of commercial tobacco use.

---

References

• 1. Brandariz JR, et al. Estimated impact of a tobacco-elimination strategy on lung-cancer mortality in 185 countries: A population-based cohort simulation study. Lancet Public Health. 2024.
• 2. Puljević C, et al. Closing the gaps in tobacco-endgame evidence: A scoping review. Tob Control. 2022;31(2):365–375.
• 3. McDaniel PA, Smith EA, Malone RE. The tobacco endgame: a qualitative review and synthesis. Tob Control. 2016 Sep;25(5):594-604. doi: 10.1136/tobaccocontrol-2015-052356. Epub 2015 Aug 28. PMID: 26320149; PMCID: PMC5036259.
• 4. Hoek J, Edwards R, Waa A. From social accessory to societal disapproval: smoking, social norms and tobacco endgames. Tob Control. 2022 Mar;31(2):358-364. doi: 10.1136/tobaccocontrol-2021-056574. PMID: 35241613.
• 5. National Institute on Minority Health and Health Disparities. Tobacco Endgame: Improving Outcomes for People from Marginalized Communities. 2023.
• 6. IASLC Tobacco Control and Smoking Cessation Committee. Position Statement on Documentation of Tobacco Use in Cancer Clinical Trials. 2025.
• 7. Benowitz NL, Donny EC, Hatsukami DK. Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. Addiction. 2017 Jan;112(1):6-7. doi: 10.1111/add.13534. Epub 2016 Aug 23. PMID: 27555354; PMCID: PMC5518737.
• 8. Tidey JW, Snell LM, Colby SM, Cassidy RN, Denlinger-Apte RL. Effects of very low nicotine content cigarettes on smoking across vulnerable populations. Prev Med. 2022 Dec;165(Pt B):107099. doi: 10.1016/j.ypmed.2022.107099. Epub 2022 May 26. PMID: 35642796; PMCID: PMC9699899.
• 9. US Food and Drug Administration. FDA Proposes Significant Step Toward Reducing Nicotine to Minimally or Nonaddictive Level in Cigarettes and Certain Other Combusted Tobacco Products. 2025.
• 10. Henriksen L. The retail environment for tobacco: a barometer of progress toward the endgame. Tob Control. 2015;24(e1):e1-e2.
• 11. Wilson N, Thomson GW, Edwards R, Blakely T. Potential advantages and disadvantages of an endgame strategy: a ‘sinking lid’ on tobacco supply. Tob Control. 2013 May;22 Suppl 1(Suppl 1):i18-21. doi: 10.1136/tobaccocontrol-2012-050791. PMID: 23591499; PMCID: PMC3632985.
• 12. Berrick AJ. The tobacco-free generation proposal. Tob Control. 2013 May;22 Suppl 1(Suppl 1):i22-6. doi: 10.1136/tobaccocontrol-2012-050865. PMID: 23591500; PMCID: PMC3632970.
• 13. Maldives Becomes First Nation to Ban Smoking for an Entire Generation. Pulmonology Advisor. Published November 10, 2025. Accessed February 17, 2026. https://www.pulmonologyadvisor.com/news/maldives-becomes-first-nation-to-ban-smoking-for-an-entire-generation/.
• 14. Mukand NH, Max WB, Colonna R, Andersen-Rodgers E, White JS. Effect of tobacco sales bans on retail sales in Beverly Hills and Manhattan Beach, California, USA: a synthetic difference-in-differences analysis. Tob Control. 2025 Nov 25:tc-2024-059184. doi: 10.1136/tc-2024-059184. Epub ahead of print. PMID: 41219114; PMCID: PMC12778735.
• 15. McDaniel PA, Smith EA, Malone RE, Retailer experiences with tobacco sales bans: lessons from two early adopter jurisdictions Tobacco Control 2024;33:739-744.
• 16. UK Parliament. Tobacco and Vapes Bill: research briefing. 2024.
• 17. Public Health Law Center. Kicking industry butts: Santa Cruz County adopts first-in-the-nation filtered cigarette sales ban. 2025.
• 18. Novotny TE, Slaughter E. Tobacco Product Waste: An Environmental Approach to Reduce Tobacco Consumption. Curr Environ Health Rep. 2014 May 6;1(3):208-216. doi: 10.1007/s40572-014-0016-x. PMID: 25152862; PMCID: PMC4129234.
• 19. World Health Organization. Guidelines for implementation of Article 14 of the WHO Framework Convention on Tobacco Control. 2010.
• 20. US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970.